Wei Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Zhou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andrew V. Kossenkov
The Wistar Institute, Philadelphia, Pennsylvania
2 shared publications - Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
2 shared publications - Chen Wang
Peking University China–Japan Friendship School of Clinical Medicine, Beijing, China
2 shared publications - Dajiang Guo
Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology Prince of Wales Hospital, The Chinese University of Hong Kong Shatin Hong Kong
2 shared publications - Iris Müller
Cell Biology Program and Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications - Jianhuang Lin
Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania
2 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity
Table S3 shows the correlation between TRIM28 expression and clinical response to anti-PD1 therapy in melanoma based on a published proteomics database
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity
Table S3 shows the correlation between TRIM28 expression and clinical response to anti-PD1 therapy in melanoma based on a published proteomics database
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figures S1-S5 from The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity
Supplementary Figures S1-S5 + Legends
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigures S1-S5 from The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity
Supplementary Figures S1-S5 + Legends
- RetractionOpen Access
- 28 September 2021
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 14, 4933-4934
microRNA-605 Inhibits the Oncogenicity of Non-Small-Cell Lung Cancer by Directly Targeting Forkhead Box P1 [Retraction]
Retraction for the article microRNA-605 inhibits the oncogenicity of non-small-cell lung cancer by directly targeting Forkhead Box P1
- 28 September 2021
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 14, 4933-4934
RetractionOpen AccessmicroRNA-605 Inhibits the Oncogenicity of Non-Small-Cell Lung Cancer by Directly Targeting Forkhead Box P1 [Retraction]
Retraction for the article microRNA-605 inhibits the oncogenicity of non-small-cell lung cancer by directly targeting Forkhead Box P1
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Mass Spectrometry and Computer Simulation Predict the Interactions of AGPS and HNRNPK in Glioma
Ether lipids are overexpressed in malignant tumor and play an important role in tumor process. Glioma is the most common malignant central nervous system tumor, and the content of ether lipids is higher than that of normal tissues. Alkylglycerone phosphate synthase (AGPS) is a key enzyme in the synthesis of ether esters and plays a vital role in maintaining the morphology and pathogenic properties of tumor cells. The cell proliferation and the content of tumor‐related lipid such as monoalkylglycerol ether (MAGe), lysophosphatidic acid ether (LPAe), lysophosphatidylcholine ether (LPCe), lysophosphatidylethanolamine ether (LPEe), phosphatidyl inositol (PI), phosphatidylcholine (PC), and phosphatidylserine (PS) were suppressed after AGPS silencing in U251, H4, and TJ905 cells; however, heterogeneous nuclear ribonucleoprotein K (HNRNPK) could reverse the above phenomenon such as cellar proliferation and ether lipid secretion. We found that HNRNPK was the target protein of AGPS by coimmunoprecipitation and mass spectrometry assay and verified by western blot assay in U251 cells. It confirmed that AGPS and HNRNPK are coexpressed in the cellular nucleus by a confocal laser microscope. The main protein‐protein interaction mechanism between AGPS and HNRNPK is hydrogen bond, conjugation bond, hydrophobic bond, and electrostatic force by computer simulation prediction.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessMass Spectrometry and Computer Simulation Predict the Interactions of AGPS and HNRNPK in Glioma
Ether lipids are overexpressed in malignant tumor and play an important role in tumor process. Glioma is the most common malignant central nervous system tumor, and the content of ether lipids is higher than that of normal tissues. Alkylglycerone phosphate synthase (AGPS) is a key enzyme in the synthesis of ether esters and plays a vital role in maintaining the morphology and pathogenic properties of tumor cells. The cell proliferation and the content of tumor‐related lipid such as monoalkylglycerol ether (MAGe), lysophosphatidic acid ether (LPAe), lysophosphatidylcholine ether (LPCe), lysophosphatidylethanolamine ether (LPEe), phosphatidyl inositol (PI), phosphatidylcholine (PC), and phosphatidylserine (PS) were suppressed after AGPS silencing in U251, H4, and TJ905 cells; however, heterogeneous nuclear ribonucleoprotein K (HNRNPK) could reverse the above phenomenon such as cellar proliferation and ether lipid secretion. We found that HNRNPK was the target protein of AGPS by coimmunoprecipitation and mass spectrometry assay and verified by western blot assay in U251 cells. It confirmed that AGPS and HNRNPK are coexpressed in the cellular nucleus by a confocal laser microscope. The main protein‐protein interaction mechanism between AGPS and HNRNPK is hydrogen bond, conjugation bond, hydrophobic bond, and electrostatic force by computer simulation prediction.